Some thoughts before the July 31st.  * Is the #C4CT

New Post Public Reply Private Reply Replies (2) Message Board
Mauibound

Some thoughts before the July 31st. 

* Is the #C4CT website up to date?
* Is Dr. Kirby presenting on behalf of the company, per GC
* if he is, is Dr. Kirby being introduced as a BOA or CMO
I have emailed Aimee with the above questions and will post any updates or responses.

Questions I don't have an answers to:

Can the Gov't give Grants or Contracts to not yet Approved FDA diagnostic tests?

IE - Fed grants or contracts for testing soldiers 

"As we prepare to launch our blood diagnostic LymPro Test ® for Alzheimer's disease in the second half of 2014, we believe it is critical to identify populations who are at the highest risk of developing Alzheimer's disease so that we may conduct clinical research to identify common pathways among those who progress to Alzheimer's disease," said Gerald E. Commissiong, President & CEO of Amarantus. "Traumatic Brain Injury is a clear risk factor that we believe accelerates an already-present predisposition for Alzheimer's disease. Current and former athletes and soldiers who have been exposed to multiple concussions and sub-concussive events should be on high alert for symptomatology of early Alzheimer's disease."

As mentioned in the PR specifically attached w/the #C4CT Summit.
http://www.marketwatch.com/story/amarantus-an..._news_stmp

Without getting into ANY political debates, with having The Honorable Chaka Fattah Member of Congress giving the Opening Keynote Address and his personal mission in wanting to address Alzheimer's, TBI and the correlation to the two, I wonder is there is a connection that we do not know about.

GC has said many times over in essence  -
I don't worry about share price. Let the science speak for itself.

And yet, he is the one when asked 
"@G_Commish Estimate of range of where you'd like see share price before reverse split/up-list? Glad it's in 2015."
GC voluntarily offers up ".@eyedo_2015 We do not know a reverse is needed. #AskAMBS"

https://mobile.twitter.com/G_Commish/status/4...8794665984

The worst thing a small co. can do is call attention to itself on a global scale and produce failing numbers. GC has intimated this, so why on Earth would he 
A) Intro $AMBS at AAIC 
B) let it be known he will be delivering new updated #'s at the #C4CT
C) bring up the idea of possibly NOT needing an R/S
D) bring up the terms like  Financial Engineering 
E) continually speak of taking care of long term investors
F) have an unwavering stance that LymPro Test(R) to market & up listing will both happen 2H14

He would have to be an absolute CLOWN to continually make remarks and statements that are so entirely outlandish and FALSE,  no?

That's crazy talk, though, none are promises, but legitimate goals set forth by him. For whatever reasoning, he sees it as financially plausible.

What news will be coming out soon regarding MANF. Not JV or partnering or even grants, all possible too, but as in research in regards to:

Wolfram's Syndrome and MANF as Dr. Urano aims to cure! As in eradicate a disease. 

Scientists rarely take time to celebrate, Japanese scientists celebrate even less, because the science is not about them, it's about their team, the disease and the common goal to eradicate that disease. 

So, for Dr. Urano to publicly announce he has just submitted a paper and show himself "celebrating", that speaks volumes.

"Just sent out an research article on Wolfram syndrome. Cheers!"  Fumi instagram.com/p/qSvNTztW1N/
6:44pm - 10 Jul 14

And then to follow it up by Stating his intentions of coming up with a cure and the process will be TROUGH MANF, well I don't have a clue what else anyone needs to be reassured in this company, the people who are running it, associated with it  and everyone on the forefront of finding cures...

Oh and last before I get off my soapbox for the day, Any CLOWN who refers to that other test AMYVID other than AMYVID is dismissing and degrading every single person who has worked on it  and every single patient and family member that is dealing or has dealt with that disease.
Refer to it by its proper name you Arrogant CLOWN and pay respects to the community who is working on helping those who are suffering!

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 232

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 290

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 373

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 104

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 38

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 675

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 144

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 136

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 607

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 21

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Cassava Sciences Takes Strategic Steps Amid Clinical Developments

Updated Category News Views 241

Cassava Sciences Provides Key Business Update Cassava Sciences, Inc. (NASDAQ: SAVA), a biotechnology company dedicated to developing innovative treatments for central nervous system disorders, has shared an important business update that affects both its operations and strategic direction. Important Study Results and Future Plans Recent data from the Phase 3 RETHINK-ALZ...

Continue Reading
ColdVentures Welcomes Dr. Barrak Alahmad as Strategic Advisor

Updated Category News Views 164

ColdVentures Expands Leadership with Key Appointment ColdVentures, a pioneering medical device company focused on addressing heat-related illnesses, has taken a significant step forward by appointing Dr. Barrak Alahmad as a strategic advisor. Dr. Alahmad, known for his expertise in environmental health and climate change, brings a wealth of knowledge to the role,...

Continue Reading
Season Group Hits Top 15% with EcoVadis Silver Medal

Updated Category News Views 40

Season Group's Silver Medal Moment Well, it's not every day that a company gets a pat on the back for actually doing something good, but that's what you have here with Season Group snagging the EcoVadis Silver Medal. It’s like the Oscars for sustainability, and it puts them in the top 15% of companies assessed globally by these sustainability gurus. That’s a title...

Continue Reading
LSPedia Achieves Notable Recognition in Business Category

Updated Category News Views 144

LSPedia Celebrated for Excellence in Business LSPedia is thrilled to announce its recent inclusion in Inc.'s 2024 Best in Business list, specifically in the Software as a Service category. This prestigious recognition highlights organizations that are industry leaders and stand out for their impactful achievements. A Testament to Industry Leadership In recognizing...

Continue Reading
Bev Colan Appointed as President of Venn Workforce Optimization

Updated Category News Views 216

Venn Workforce Optimization Welcomes New Leadership In an exciting development for Venn Workforce Optimization, Bev Colan has been named the company president. This marks a significant step for the organization, which specializes in locum tenens optimization and workforce solutions technology. Bev Colan: A Proven Leader Bev Colan joins the Venn team with over 20 years of...

Continue Reading